The JAK Pills That Changed Severe Alopecia

What alopecia areata is, and why a pill can help

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, typically producing patchy hair loss on the scalp; its course is unpredictable, and while treatments can promote regrowth, there is no cure 2Ref 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (2024).Alopecia Areata.Definitional overview: alopecia areata is an autoimmune disease attacking hair follicles, with an unpredictable course, no cure, and the potential to affect any hair-bearing skin including eyebrows, eyelashes, and beard.. Because the underlying problem is immune signaling rather than the hair follicle itself being damaged beyond repair, a drug that quiets that signaling can allow follicles to resume growing hair they were never permanently prevented from producing.

Baricitinib works by blocking JAK1 and JAK2, enzymes involved in relaying the inflammatory signals that drive the immune attack in alopecia areata 1Ref 1King B, Ohyama M, Kwon O, et al. (2022).Two Phase 3 Trials of Baricitinib for Alopecia Areata.BRAVE-AA1 and BRAVE-AA2 phase 3 trials showing oral baricitinib (JAK1/2 inhibitor) is superior to placebo for hair regrowth (SALT ≤20 at week 36) in adults with severe alopecia areata; basis for the first systemic FDA approval in AA.. The same class of drug is used elsewhere in dermatology in different forms — a topical JAK inhibitor is used for repigmentation in vitiligo 3Ref 3Rosmarin D, Passeron T, Pandya AG, et al. (2022).Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.Illustrates the JAK inhibitor drug class used topically in a different autoimmune skin disease (vitiligo), used here to contextualize JAK inhibitors as a class rather than a single alopecia-specific drug., and oral JAK inhibitors are also part of systemic treatment for moderate-to-severe eczema 4Ref 4Sidbury R, Davis DM, Alikhan A, et al. (2024).Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.Illustrates oral JAK inhibitors used as systemic therapy in a different inflammatory skin disease (atopic dermatitis), used here to contextualize JAK inhibitors as a drug class used across dermatology. — which is part of why this drug class has drawn so much attention across autoimmune skin disease generally, not only in alopecia areata.

How severity is measured, and who a JAK inhibitor pill is for

How is alopecia areata severity measured comes down mostly to what fraction of the scalp has lost hair, tracked with a standardized scalp-coverage score; the baricitinib trials defined a meaningful response as reaching a score of 20 or lower, meaning 80 percent or more of scalp hair present, by roughly week 36 1Ref 1King B, Ohyama M, Kwon O, et al. (2022).Two Phase 3 Trials of Baricitinib for Alopecia Areata.BRAVE-AA1 and BRAVE-AA2 phase 3 trials showing oral baricitinib (JAK1/2 inhibitor) is superior to placebo for hair regrowth (SALT ≤20 at week 36) in adults with severe alopecia areata; basis for the first systemic FDA approval in AA.. That SALT score alopecia threshold is what regulators and trial investigators used to decide whether the drug was actually working, rather than relying on how a person or their doctor felt about visible improvement alone.

Systemic alopecia threshold for actually starting a JAK inhibitor pill is generally severe, extensive scalp involvement — not early or patchy disease — since a drug taken daily with its own monitoring requirements is reserved for cases where the extent of hair loss justifies that tradeoff.

What the trials actually showed

Two identically designed, placebo-controlled trials, BRAVE-AA1 and BRAVE-AA2, enrolled adults with severe alopecia areata and found that significantly more people taking oral baricitinib reached adequate scalp hair regrowth by week 36 than people taking placebo 1Ref 1King B, Ohyama M, Kwon O, et al. (2022).Two Phase 3 Trials of Baricitinib for Alopecia Areata.BRAVE-AA1 and BRAVE-AA2 phase 3 trials showing oral baricitinib (JAK1/2 inhibitor) is superior to placebo for hair regrowth (SALT ≤20 at week 36) in adults with severe alopecia areata; basis for the first systemic FDA approval in AA.. Running the same trial design twice, independently, and getting the same result both times is part of why regulators found the evidence convincing enough to approve the drug specifically for this disease — a single positive trial can be a fluke, but two separate trials pointing the same direction is much harder to explain away.

Not everyone who starts baricitinib reaches that regrowth threshold, which is why response is checked at a defined point in treatment rather than assumed, and why extensive, longstanding hair loss doesn't guarantee a full response even on an effective drug.

Trial participants in BRAVE-AA1 and BRAVE-AA2 had, on average, lost most of their scalp hair for years before enrolling, not a recent or mild patch — which matters for interpreting the results, since a drug shown to work in longstanding, severe disease is a different claim than one tested only in early or mild cases 1Ref 1King B, Ohyama M, Kwon O, et al. (2022).Two Phase 3 Trials of Baricitinib for Alopecia Areata.BRAVE-AA1 and BRAVE-AA2 phase 3 trials showing oral baricitinib (JAK1/2 inhibitor) is superior to placebo for hair regrowth (SALT ≤20 at week 36) in adults with severe alopecia areata; basis for the first systemic FDA approval in AA.. That population detail is part of why the approval specifically covers severe alopecia areata rather than the condition broadly.

Where this sits on the alopecia areata treatment ladder

Alopecia areata treatment options generally start well before an oral JAK inhibitor — topical or injected corticosteroids for smaller patches, and other localized measures for limited disease — with a systemic pill reserved for more extensive, harder-to-treat cases 2Ref 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (2024).Alopecia Areata.Definitional overview: alopecia areata is an autoimmune disease attacking hair follicles, with an unpredictable course, no cure, and the potential to affect any hair-bearing skin including eyebrows, eyelashes, and beard.. Where minoxidil fits in alopecia areata is as a possible adjunct rather than a primary driver of regrowth in this disease; minoxidil's strongest evidence comes from androgenetic alopecia, the pattern hair loss it was originally developed and studied for, not from alopecia areata specifically 5Ref 5Adil A, Godwin M (2017).The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.Evidence that minoxidil and finasteride are effective specifically for androgenetic alopecia (pattern hair loss), used to distinguish that evidence base from alopecia areata and to contextualize minoxidil's more limited role there..

Alopecia areata treatment guideline thinking generally treats extent and duration of hair loss, along with how much it's affecting someone, as the factors that push a case toward a systemic option like a JAK inhibitor rather than continuing with topical or injected treatment indefinitely.

Alopecia areata vs. pattern hair loss

Alopecia areata vs pattern loss is a distinction worth getting right before starting any treatment, since they're different diseases with different drugs behind them. Alopecia areata versus androgenetic alopecia comes down to pattern and mechanism: alopecia areata tends to produce sharply defined round or oval patches from an autoimmune attack, while androgenetic alopecia is a gradual, hormonally driven thinning — typically a receding hairline or crown thinning in men, and diffuse thinning in women — with a treatment evidence base built around minoxidil and finasteride rather than immune-modulating drugs 5Ref 5Adil A, Godwin M (2017).The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.Evidence that minoxidil and finasteride are effective specifically for androgenetic alopecia (pattern hair loss), used to distinguish that evidence base from alopecia areata and to contextualize minoxidil's more limited role there..

Alopecia areata vs male pattern baldness matters practically because a JAK inhibitor pill approved for alopecia areata isn't studied or indicated for androgenetic alopecia, and using the wrong framework to think about a case can lead someone toward the wrong category of treatment entirely.

Hair loss beyond the scalp

Alopecia beyond the scalp is common in alopecia areata, since the same autoimmune process can affect any hair-bearing skin, not only the scalp 2Ref 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (2024).Alopecia Areata.Definitional overview: alopecia areata is an autoimmune disease attacking hair follicles, with an unpredictable course, no cure, and the potential to affect any hair-bearing skin including eyebrows, eyelashes, and beard.. Eyebrow eyelash alopecia and patchy loss in the beard are recognized presentations of the same disease, and alopecia in brows and beard can be just as functionally and socially significant as scalp involvement, sometimes more so, depending on which areas are affected.

Because systemic treatment works on the underlying immune process rather than on one specific patch, a JAK inhibitor pill that's working can improve hair growth across all affected sites at once, scalp and otherwise, rather than requiring a separate treatment decision for each area.

For someone whose hair loss is limited to eyebrows or eyelashes without significant scalp involvement, the calculus around starting a systemic pill can look different than it does for someone with widespread scalp loss, since the visible and functional impact of eyebrow or eyelash loss doesn't scale neatly with a scalp-based severity score. That's a case where a scalp-coverage score alone can undersell how much a treatment decision matters to the person living with it.